Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates [Yahoo! Finance]
Passage Bio, Inc. (PASG)
Company Research
Source: Yahoo! Finance
FDA feedback from recent Type C meeting indicated a randomized controlled registrational trial will be required for PBFT02 in FTD-GRN The Company initiated a strategic review process intended to maximize shareholder value PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations. In addition, the Company shared feedback from a recent Type C meeting with the United States Food and Drug Administration (FDA) on the likely registrational pathway for PBFT02 in FTD- GRN. The Company has also announced it has engaged Wedbush PacGrow as a financial advisor and has initiated a review of strategic alternatives to maximize shareholder value. Will Chou, M.D., president and
Show less
Read more
Impact Snapshot
Event Time:
PASG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PASG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PASG alerts
High impacting Passage Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PASG
News
- Passage Bio (PASG) is now covered by Wedbush. They set a "reduce" rating on the stock.MarketBeat
- Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesGlobeNewswire
- Passage Bio (PASG) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $30.00 price target on the stock.MarketBeat
- Passage Bio (PASG) had its price target lowered by Canaccord Genuity Group Inc. from $67.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
PASG
Earnings
- 11/10/25 - Beat
PASG
Sec Filings
- 4/20/26 - Form 8-K
- 4/7/26 - Form ARS
- 4/7/26 - Form DEFA14A
- PASG's page on the SEC website